, Volume 30, Issue 3, pp 262–264 | Cite as

Effects of octanoate on the electrical activity of Purkinje fibres

  • J. BorbolaJr.
  • J. Gy. Papp
  • L. Szekeres


Morphine Substantia Nigra Action Potential Duration Octanoate Purkinje Fibre 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Am Beispiel von Octanoat (Kaprylsäure) wird nachgewiesen, dass Fettsäure das Aktionspotential von Purkinje-Fasern des Kalbes verändert. Dieselben Octanoaktonzentrationen von 2,4 mM unterdrückten auch die spontanen Aktivitäten isolierter Herzkammer-Streifenpräparate.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    M. F. Oliver, V. A. Kurien andT. W. Greenwood, Lancet1, 710 (1968).CrossRefPubMedGoogle Scholar
  2. 2.
    V. A. Kurien, P.A. Yates andM. F. Oliver Lancet2, 185 (1969).CrossRefPubMedGoogle Scholar
  3. 3.
    V. A. Kurien, P. A. Yates, M. F. Oliver, Eur. J. clin. Invest.1, 225 (1971).PubMedGoogle Scholar
  4. 4.
    H. L. Rutenberg, J. C. Pamintuan andL. Soloff, Lancet2, 559 (1969).CrossRefPubMedGoogle Scholar
  5. 5.
    P. G. Nelson, Br. med. J.3, 735 (1970).CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    L. H. Opie, R. M. Norris, M. Thomas, A. J. Holland, P. Owen andS. van Norden, Lancet1, 818 (1971).CrossRefPubMedGoogle Scholar
  7. 7.
    P. L. Friedman, J. Stewart, B. F. Hoffman, andA. L. Witt, Circulation46, Suppl.2, 10 (1972).Google Scholar
  8. 8.
    L. Szekeres andE. M. Vaughan-Williams, J. Phisiol., Lond.160, 470 (1962).CrossRefGoogle Scholar
  9. 9.
    J. Gy. Papp andE. M. Vaughan-Williams, Br. J. Pharmac.37, 380 (1969).CrossRefGoogle Scholar
  10. 10.
    L. H. Opie, Nature, Lond.227, 1055 (1970).CrossRefGoogle Scholar
  11. 11.
    A. H. Henderson, A. S. Most, W. W. Parmley, R. Gorlin andE. H. Sonnenblick, Circulation Res.26, 439 (1970).CrossRefPubMedGoogle Scholar
  12. 12.
    W. Trautwein, V. Gottstein andJ. Dudel, Pflüger's Arch. ges. Physiol.260, 40 (1954).CrossRefGoogle Scholar
  13. 13.
    O. Hauswirth, Circulation Res.24, 745 (1969).CrossRefPubMedGoogle Scholar
  14. 14.
    P. Cranefield, A. L. Wit andB. F. Hoffman, Circulation47, 190 (1973).CrossRefPubMedGoogle Scholar
  15. 15.
    W. Trautwein, Verh. dt. Ges. Kreislauf-Forsch.30, 40 (1964).Google Scholar
  16. 16.
    J. Gy. Papp andL. Szekeres, Eur. J. Pharmac.3, 15 (1968).CrossRefGoogle Scholar
  17. 17.
    L. Szekeres andJ. Gy. Papp,Experimental Cardiac Arrhythmias and Antiarryhthmic Drugs (Akadémiai Kiadó, Budapest 1971), p. 14–16, 77 and 217.Google Scholar
  18. 18.
    V. A. Kurien, M. F. Oliver, Lancet7, 813 (1970).CrossRefGoogle Scholar
  19. 19.
    J. Borbola Jr., J. Gy. Papp andL. Szekeres, unpublished results.Google Scholar
  20. 20.
    A. F. Willebrands, H. F. Ter Welle andS. A. J. Tasseron, J. molec. cell. Cardiol.5, 259 (1973).CrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag 1974

Authors and Affiliations

  • J. BorbolaJr.
    • 1
  • J. Gy. Papp
    • 1
  • L. Szekeres
    • 1
  1. 1.Department of PharmacologyUniversity Medical SchoolSzegedHungary

Personalised recommendations